JP Morgan Chase
AKTX

JP Morgan Chase’s Akari Therapeutics AKTX Stock Holding History

JP Morgan Chase’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Hold
0
– – – 6885
2023
Q1 		– Hold
0
– – – 6654
2017
Q3 		– Sell
-3
Closed -$11K – 4949
2017
Q2 		$11K Buy
+3
New +$23.7K ﹤0.01% 4638

Other funds holding AKTX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
BMCM
Bryn Mawr Capital Management Philadelphia, Pennsylvania $2.06B AUM 19.82% 1-Year Est. Return

JP Morgan Chase's AKTX Position: Q2 2023 in Review

JP Morgan Chase held its Akari Therapeutics (AKTX) position steady in Q2 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #6885.

JP Morgan Chase first reported a position in AKTX in Q2 2017 and has held it in 1 quarter since. The position peaked at $11K in Q2 2017. 16 funds tracked by Wall St. Rank hold AKTX as of Q2 2023.

  • JP Morgan Chase held 0 shares of Akari Therapeutics worth $0 as of Q2 2023.
  • JP Morgan Chase left its Akari Therapeutics share count unchanged in Q2 2023.
  • Akari Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2023, its #6885 holding.
  • JP Morgan Chase first reported a position in Akari Therapeutics in Q2 2017 and has held it in 1 quarter since.
  • JP Morgan Chase's Akari Therapeutics position peaked at $11K in Q2 2017.
  • 16 funds tracked by Wall St. Rank held Akari Therapeutics as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.